In Relapsed/Refractory Myeloma, Blenrep-Based Regimen Produces PFS Advantage.

Published Date: 04 Jun 2024

In this context, the second belantamab mafodotin-containing triplet to demonstrate potency.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Timely ‘Nudges’ Help Spur Talks on Patient Care Goals

2.

Losing a reward can affect your motivation and performance.

3.

Study suggests radiation therapy benefits misjudged when clinical factors alone guide breast cancer treatment

4.

Which Salvage Therapy Is Best for Recurrent Prostate Cancer?

5.

In Relapsed/Refractory Myeloma, Blenrep-Based Regimen Produces PFS Advantage.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot